London
· Delayed Price · Currency is GBP · Price in USD Tandem Diabetes Care Statistics
Total Valuation
Tandem Diabetes Care has a market cap or net worth of GBP 1.96 billion. The enterprise value is 1.96 billion.
| Market Cap | 1.96B |
| Enterprise Value | 1.96B |
Important Dates
The next estimated earnings date is Wednesday, February 26, 2025.
| Earnings Date | Feb 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.91% |
| Shares Change (QoQ) | +0.84% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 65.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 11.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -20.72 |
| EV / Sales | 2.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -174.36 |
Financial Position
The company has a current ratio of 2.90, with a Debt / Equity ratio of 2.00.
| Current Ratio | 2.90 |
| Quick Ratio | 2.24 |
| Debt / Equity | 2.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -31.58 |
| Interest Coverage | -19.99 |
Financial Efficiency
Return on equity (ROE) is -45.96% and return on invested capital (ROIC) is -12.72%.
| Return on Equity (ROE) | -45.96% |
| Return on Assets (ROA) | -9.69% |
| Return on Invested Capital (ROIC) | -12.72% |
| Return on Capital Employed (ROCE) | -21.06% |
| Revenue Per Employee | 265,596 |
| Profits Per Employee | -39,413 |
| Employee Count | 2,400 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 2.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +56.89% |
| 50-Day Moving Average | 34.27 |
| 200-Day Moving Average | 39.31 |
| Relative Strength Index (RSI) | 58.08 |
| Average Volume (20 Days) | 240 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.53 |
Income Statement
In the last 12 months, Tandem Diabetes Care had revenue of GBP 637.43 million and -94.59 million in losses. Loss per share was -1.45.
| Revenue | 637.43M |
| Gross Profit | 317.40M |
| Operating Income | -109.74M |
| Pretax Income | -91.92M |
| Net Income | -94.59M |
| EBITDA | -97.51M |
| EBIT | -109.74M |
| Loss Per Share | -1.45 |
Balance Sheet
The company has 353.13 million in cash and 355.10 million in debt, giving a net cash position of -1.97 million.
| Cash & Cash Equivalents | 353.13M |
| Total Debt | 355.10M |
| Net Cash | -1.97M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 177.36M |
| Book Value Per Share | 2.70 |
| Working Capital | 368.24M |
Cash Flow
In the last 12 months, operating cash flow was 4.69 million and capital expenditures -15.94 million, giving a free cash flow of -11.24 million.
| Operating Cash Flow | 4.69M |
| Capital Expenditures | -15.94M |
| Free Cash Flow | -11.24M |
| FCF Per Share | n/a |
Margins
Gross margin is 49.79%, with operating and profit margins of -17.22% and -14.84%.
| Gross Margin | 49.79% |
| Operating Margin | -17.22% |
| Pretax Margin | -14.42% |
| Profit Margin | -14.84% |
| EBITDA Margin | -15.30% |
| EBIT Margin | -17.22% |
| FCF Margin | n/a |
Dividends & Yields
Tandem Diabetes Care does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.91% |
| Shareholder Yield | -0.91% |
| Earnings Yield | -4.83% |
| FCF Yield | -0.57% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Tandem Diabetes Care has an Altman Z-Score of 1.26. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.26 |
| Piotroski F-Score | n/a |